Researchers from two Lithuanian universities have developed a patient-safe monitoring technology to identify and manage individual factors provoking atrial fibrillation.
It’s a CRISPR-mas miracle: CRISPR approval marks early present for Vertex
Share this article Figure 1: CRISPR drug count per active stage of development. Credit: GlobalData. Last month, Vertex Pharmaceuticals and CRISPR Therapeutics made history, by